Table 2. Correlations of clinicopathological parameters with SIRT3 expression.

Parameters	Total effect or subgroup analyses	Studies [ref. no.]	Heterogeneity		Model	Outcomes
			I2%	P value		OR (95% CI)	P value
Cancer/non-cancer tissues	Total	[5, 13, 29–34]	83	<0.00001	Random	0.34 (0.12, 0.99)	0.05
	Gastric cancer	[13, 29, 30]	91	<0.0001	Random	0.97 (0.12, 7.89)	0.98
	Hepatocellular carcinoma	[31, 32]	0	0.96	Fixed	0.04 (0.01, 0.16)	<0.0001
	Others	[5, 33, 34]	85	0.001	Random	0.43 (0.08, 2.44)	0.34
Lymph node metastasis	Total	[5, 8, 9, 13, 29]	78	0.001	Random	1.64 (0.80, 3.39)	0.18
(metastasis+ vs. metastasis-)	Breast cancer	[5, 8]	34	0.22	Fixed	2.20 (1.49, 3.26)	<0.0001
	Gastric cancer	[13, 29]	79	0.03	Random	0.69 (0.13, 3.62)	0.66
	Other	[9]	-	-	-	4.22 (2.00, 8.93)	0.0002
Differentiation (poorly vs. moderate/well differentiated)	Total	[11–14, 29, 31, 32]	57	0.03	Random	0.46 (0.29, 0.74)	0.001
	Gastric cancer	[13, 14, 29]	50	0.13	Fixed	0.33 (0.21, 0.50)	<0.00001
	Hepatocellular carcinoma	[11, 12, 31, 32]	4	0.37	Fixed	0.69 (0.48, 0.98)	0.04
Tumor stage (I/II vs. III/IV)	Total	[9, 10, 12–14, 29]	82	<0.0001	Random	1.68 (0.87, 3.25)	0.12
	Gastric cancer	[13, 14, 29]	86	0.0007	Random	3.09 (0.76, 12.54)	0.11
	Others	[9, 10, 12]	82	0.004	Random	1.09 (0.49, 2.42)	0.84
Tumor size (≥5cm vs. <5cm)	Total	[9, 12, 29, 31, 32]	0	0.93	Fixed	0.85 (0.60, 1.22)	0.38
	Hepatocellular carcinoma	[12, 31, 32]	0	0.89	Fixed	0.81 (0.51, 1.29)	0.38
	Others	[9, 29]	0	0.48	Fixed	0.92 (0.53, 1.60)	0.76
Gender (male vs. female)	Total	[9–13, 29, 31, 32]	12	0.33	Fixed	1.06 (0.79, 1.41)	0.71
	Gastric cancer	[13, 29]	0	0.34	Fixed	1.66 (0.78, 3.55)	0.19
	Hepatocellular carcinoma	[11, 12, 31, 32]	0	0.82	Fixed	1.32 (0.84, 2.08)	0.22
	Others	[9, 10]	31	0.23	Fixed	0.73 (0.47, 1.13)	0.16
ER (positive vs. negative)	Breast cancer	[5, 8]	66	0.09	Random	1.92 (0.95, 3.90)	0.07
PR (positive vs. negative)	Breast cancer	[5, 8]	92	0.0004	Random	0.95 (0.22, 4.10)	0.95

OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor.